print_label | resize_label

For the long-term maintenance treatment of COPDContact us

Here's how you can reach us:

  • General Questions
  • Media-related
  • Outside the US?

General Questions

 Contact us by phone 

If you are in the United States and would like additional information regarding AstraZeneca products, or you are a third party with an offer of services for AstraZeneca, you can contact the AstraZeneca Information Center by phone at 1-800-236-9933 (Monday–Friday, 8 AM–6 PM ET, excluding holidays).

 Contact us online 

If you are outside of the United States, please visit the AstraZeneca global site.

If you are in the United States and would like to request information, please select from the following options:


If you are a professional member of the media and have media-related questions, please visit our media contacts page on our AstraZeneca corporate site.

Outside the US?

This Web site is intended for people seeking information on AstraZeneca's business in the United States. If you are outside of the United States or are looking for information about AstraZeneca's international business, please visit the AstraZeneca global site.


  • TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or any of the excipients
  • TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (ie, rescue therapy)
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of TUDORZA PRESSAIR. Additionally, inhaled medicines, including TUDORZA PRESSAIR, may cause paradoxical bronchospasm. If any of these occurs, treatment with TUDORZA PRESSAIR should be stopped and other treatments considered
  • TUDORZA PRESSAIR should be used with caution in patients with narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of acute narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop
  • The most common adverse reactions (≥3% incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for TUDORZA PRESSAIR vs placebo, respectively


TUDORZA PRESSAIR is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Please also see the full Prescribing Information.

You may report side effects related to AstraZeneca products by clicking here.